These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17186837)

  • 21. COX-2 inhibitors: new drugs for the management of pain and inflammation.
    Hutchins V; Hutchins B
    Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
    [No Abstract]   [Full Text] [Related]  

  • 22. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.
    Harrington LS; Lucas R; McMaster SK; Moreno L; Scadding G; Warner TD; Mitchell JA
    FASEB J; 2008 Nov; 22(11):4005-10. PubMed ID: 18753249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 24. COX-2-derived prostacyclin confers atheroprotection on female mice.
    Egan KM; Lawson JA; Fries S; Koller B; Rader DJ; Smyth EM; Fitzgerald GA
    Science; 2004 Dec; 306(5703):1954-7. PubMed ID: 15550624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
    Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
    Patrignani P
    Acta Otorhinolaryngol Ital; 2003 Aug; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
    [No Abstract]   [Full Text] [Related]  

  • 28. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
    Jugdutt BI
    Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292
    [No Abstract]   [Full Text] [Related]  

  • 29. [Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].
    Pairet M; Netter P
    Therapie; 1999; 54(4):433-45. PubMed ID: 10667110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular effects of cyclooxygenase-2 inhibitors.
    Brophy JM
    Curr Opin Gastroenterol; 2007 Nov; 23(6):617-24. PubMed ID: 17906437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of antinociception by co-administration of an opioid drug (morphine) and a preferential cyclooxygenase-2 inhibitor (rofecoxib) in rats.
    Déciga-Campos M; López UG; Reval MI; López-Muñoz FJ
    Eur J Pharmacol; 2003 Jan; 460(2-3):99-107. PubMed ID: 12559369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 33. Arachidonic acid metabolism, pain and hyperalgesia: the mode of action of non-steroid mild analgesics.
    Higgs GA
    Br J Clin Pharmacol; 1980 Oct; 10 Suppl 2(Suppl 2):233S-235S. PubMed ID: 7002184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COX-2 inhibitors--a lesson in unexpected problems.
    Drazen JM
    N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
    [No Abstract]   [Full Text] [Related]  

  • 35. Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics.
    Serhan CN; Levy B
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8609-11. PubMed ID: 12861081
    [No Abstract]   [Full Text] [Related]  

  • 36. Prostanoids and inflammatory pain.
    Chen L; Yang G; Grosser T
    Prostaglandins Other Lipid Mediat; 2013; 104-105():58-66. PubMed ID: 22981510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.
    Mazario J; Gaitan G; Herrero JF
    Neuropharmacology; 2001 Jun; 40(7):937-46. PubMed ID: 11378164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiovascular events: a class effect by COX-2 inhibitors].
    Araujo LF; Soeiro Ade M; Fernandes Jde L; Serrano Júnior CV
    Arq Bras Cardiol; 2005 Sep; 85(3):222-9. PubMed ID: 16200274
    [No Abstract]   [Full Text] [Related]  

  • 39. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice.
    Darling RL; Romero JJ; Dial EJ; Akunda JK; Langenbach R; Lichtenberger LM
    Gastroenterology; 2004 Jul; 127(1):94-104. PubMed ID: 15236176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.